0HLK Stock Overview

Develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details

0HLK fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 28.4% below our estimate of its fair value

Earnings are forecast to grow 3.81% per year

Earnings grew by 20.9% over the past year

Risk Analysis

Shares are highly illiquid

Dividend of 5.38% is not well covered by free cash flows

My Notes

Capture your thoughts, links and company narrative

Krka, d. d. Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£5.1b

GSK

LSE:GSK

UK£60.6b

Animalcare Group

AIM:ANCR

UK£165.6m

AstraZeneca

LSE:AZN

UK£172.5b

Price History & Performance

Summary of share price highs, lows and changes for Krka d. d
Historical stock prices
Current Share Price	€136.50
52 Week High	€136.50
52 Week Low	€109.00
Beta	0.51
1 Month Change	0%
3 Month Change	n/a
1 Year Change	25.81%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	97.39%

Recent updates

Shareholder Returns

	0HLK	GB Pharmaceuticals	GB Market
7D	0%	0.7%	0.8%
1Y	25.8%	3.1%	10.2%

Return vs Industry: 0HLK exceeded the UK Pharmaceuticals industry which returned 0.4% over the past year.

Return vs Market: 0HLK exceeded the UK Market which returned 6.9% over the past year.

Price Volatility

Is 0HLK's price volatile compared to industry and market?
0HLK volatility
0HLK Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.7%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0HLK's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0HLK's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1954	11,745	Jože Colaric	www.krka.biz

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular, alimentary tract and metabolism, central nervous system, infections, oncology, and other diseases. The company also provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.

Krka, d. d. Fundamentals Summary

How do Krka d. d's earnings and revenue compare to its market cap?
0HLK fundamental statistics
Market cap	€4.29b
Earnings (TTM)	€359.83m
Revenue (TTM)	€1.90b

11.9x

P/E Ratio

2.3x

P/S Ratio

Is 0HLK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HLK income statement (TTM)
Revenue	€1.90b
Cost of Revenue	€825.70m
Gross Profit	€1.07b
Other Expenses	€714.99m
Earnings	€359.83m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 30, 2025

Earnings per share (EPS)	11.70
Gross Margin	56.55%
Net Profit Margin	18.93%
Debt/Equity Ratio	0%

How did 0HLK perform over the long term?

See historical performance and comparison

Dividends

5.4%

Current Dividend Yield

64%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/15 20:16
End of Day Share Price	2024/09/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Krka, d. d. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Saso Stanovnik	Alta Invest
Simon Mather	Barclays
Stephane Sumar	BNP Paribas Exane